Reduced T-cell response following a third dose of SARS-CoV-2 vaccine in infection-naïve people living with HIV
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:85 |
|---|---|
| Enthalten in: |
The Journal of infection - 85(2022), 6 vom: 01. Dez., Seite 702-769 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Moussaoui, Majdouline El [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.12.2022 Date Revised 22.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jinf.2022.09.006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34613241X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34613241X | ||
| 003 | DE-627 | ||
| 005 | 20231226030706.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jinf.2022.09.006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1153.xml |
| 035 | |a (DE-627)NLM34613241X | ||
| 035 | |a (NLM)36096313 | ||
| 035 | |a (PII)S0163-4453(22)00534-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Moussaoui, Majdouline El |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Reduced T-cell response following a third dose of SARS-CoV-2 vaccine in infection-naïve people living with HIV |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.12.2022 | ||
| 500 | |a Date Revised 22.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Antibody responses | |
| 650 | 4 | |a Breakthrough infection | |
| 650 | 4 | |a COVID-19 vaccine | |
| 650 | 4 | |a Cellular | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a Humoral | |
| 650 | 4 | |a Immune response | |
| 650 | 4 | |a Neutralisation | |
| 650 | 4 | |a Omicron | |
| 650 | 4 | |a People living with HIV | |
| 650 | 4 | |a SARS-CoV-2 mRNA vaccine | |
| 650 | 4 | |a Third dose | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Desmecht, Salomé |e verfasserin |4 aut | |
| 700 | 1 | |a Tashkeev, Aleksandr |e verfasserin |4 aut | |
| 700 | 1 | |a Lambert, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Maes, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Braghini, Joachim |e verfasserin |4 aut | |
| 700 | 1 | |a Marechal, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Quintana, Céline |e verfasserin |4 aut | |
| 700 | 1 | |a Briquet, Karine |e verfasserin |4 aut | |
| 700 | 1 | |a Gofflot, Stéphanie |e verfasserin |4 aut | |
| 700 | 1 | |a Toussaint, Françoise |e verfasserin |4 aut | |
| 700 | 1 | |a Hayette, Marie-Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Vermeersch, Pieter |e verfasserin |4 aut | |
| 700 | 1 | |a Lutteri, Laurence |e verfasserin |4 aut | |
| 700 | 1 | |a Grégoire, Céline |e verfasserin |4 aut | |
| 700 | 1 | |a Beguin, Yves |e verfasserin |4 aut | |
| 700 | 1 | |a Rahmouni, Souad |e verfasserin |4 aut | |
| 700 | 1 | |a Moutschen, Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Desmecht, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Darcis, Gilles |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infection |d 1982 |g 85(2022), 6 vom: 01. Dez., Seite 702-769 |w (DE-627)NLM012791822 |x 1532-2742 |7 nnns |
| 773 | 1 | 8 | |g volume:85 |g year:2022 |g number:6 |g day:01 |g month:12 |g pages:702-769 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jinf.2022.09.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 85 |j 2022 |e 6 |b 01 |c 12 |h 702-769 | ||